examine the disease is by dividing it into increasing complexity from the genetic defect to the clinical manifestations. To understand thrombophilia, the following definitions can help clinically define the disease process 1 : (1) genotype: the genetic makeup of an organism with reference to a single trait; the assumed cause of PS deficiency; (2) protein phenotype: the protein component made by the gene in question; the amount of PS synthesized by 3 different cell types that may or may not reflect the gene status; (3) laboratory phenotype: the measurable amount of protein produced by the gene in question. PS detection levels are measurable by various methods that may or may not correlate with the protein phenotype or genotype. (4) clinical phenotype: the expression of clinical characteristics of the protein (or lack of protein) made by a gene (with or without environmental and acquired interactions). Thrombus formation is the clinical phenotype that is assumed to be due to the PS deficiency, but many other factors may contribute to the clinical phenotype.
An organism has an impressive ability to adjust its physiology to compensate for internal (genetic) errors and to respond to environmental changes. Clinical phenotype expression is the ultimate failure of the system of complex processes with numerous components to balance the system. In theory, this complexity should allow the overall process to tolerate moderate perturbations without causing an abnormal clinical phenotype. However, in some cases, the deficiency like PS deficiency seems to overwhelm the system and express the clinical phenotype. 1 The initial question one must ask about thrombophilia is about the importance of the clinical phenotype compared with the genotype. Because thrombophilia is a complex disease, the most important clinical aspect is venous thrombosis because it can be diagnosed and treated irrespective of the genotype or the results of a laboratory assessment. However, this is usually after the occurrence of the disease process (venous thrombosis). The genetic and acquired causes of the thrombophilia are the second important aspect. However, at this time, it is not practical to identify the genotype(s) using molecular biologic methods. So we must rely on surrogate markers for the genetic defects by analyzing the protein levels found in plasma. 2, 4 This creates many issues associated with the identification of a genetic deficiency by laboratory phenotype alone.
One of the major questions from a laboratory perspective is: Does a decreased level of PS (lower than the reference limit) truly constitute a genetic deficiency? This particular question is nicely addressed by Duebgen et al in this issue of the Journal. 7 By using the clinical phenotype of thrombosis as the starting point, the authors identified the patients with levels of PS lower than the reference interval and subsequently analyzed for abnormalities in the PS gene. A number of very interesting conclusions come to light from their data. First, there is not a good correlation of low PS levels (PS activity or free PS antigen) and apparent PS genetic abnormalities. Second, Duebgen et al 7 observed that patients with deletions or stop codons had significantly lower levels of PS compared with the laboratory values for patients with no detectable mutations but abnormal levels. Finally, Duebgen et al 7 observed that the PS activity levels might be a better indicator of a genetic deficiency than free PS antigen.
The definition of PS deficiency has not been definitively established. 4, [7] [8] [9] We have always assumed that establishing a normal reference limit (average ± 2 SD) constituted the true genetic deficiency. 4, 8, 9 But from the article by Duebgen et al, 7 how do we define PS deficiency? Defining PS deficiency has always been a problem not only because of the difficulty of assay performance but also because of the role of preanalytic variables, patient-acquired factors, and multiple factors affecting the plasma levels and the effect of postvenous thrombosis. Duebgen et al 7 analyzed the results of the laboratory phenotype values compared with PS genotypes. They presented data indicating that a true PS deficiency based solely on laboratory assays may not accurately diagnose PS genotype abnormalities. This is a major observation that could affect most clinical laboratories performing thrombophilia workups. The bottomline question is: Are we accurately diagnosing PS deficiency? We thought we were, but this article suggests we may not. 7 More exploration must be made in the comparison of laboratory values of decreased PS levels and PS genotypes. 4, 8, 9 Other factors may cause falsely low results in patients without a true PS genetic deficiency. 2, 4 Unfortunately, determining the genetics of PS deficiencies is really not yet a clinical laboratory option. 2, 4, 7, 8, 10 The attempt by Duebgen et al 7 to correlate genetic mutation of PS with the presence of decreased PS plasma levels is exciting. When they found mutations where no protein is made (large deletions and nonsense mutations), the laboratory values were significantly lower than for the group of patients with levels lower than the reference limit but with no detectable mutation. 7 Is the presence of slightly abnormal plasma levels of PS activity or free PS antigen in patients with no detectable mutation truly a deficient state or is the actual lower limit of the "normal" range much lower 4, 7, 9, 11 ?
There are a number of potential causes of low PS that are not related to a genetic defects: (1) The true reference range is wider than the established ranges performed by the standard statistical method (95th percentile). (2) Acquired states in people with previous thrombosis have lower levels. (3) Calibrators of the PS assay system are not accurate or are too high. (4) The current assay systems do not measure the true function(s) of the PS molecule. Duebgen et al 7 found a correlation of the type of deficiency and the plasma level of PS. It is interesting that they found 19% to 26% PS activity and similar free PS antigen levels in the heterozygous deletions and nonsense mutations when one would expect levels of 40% to 60%. 7 The cause of these lower-than-expected levels is unclear.
For the analysis of PS in plasma, there are 3 available types of tests: PS activity, free PS antigen (which should correlate with activity), and total PS antigen. 4 The total PS antigen, which is a measure of all PS antigen material in plasma combining the free and bound forms of PS, is not very helpful for the clinical diagnosis of PS deficiency. 2, 4 Many laboratories do not perform this assay because it does not contribute significantly to the diagnostic process. 4 The other 2 assays are used to determine the presence or absence of a deficiency. However, both of these assays are sensitive to preanalytic variables and reagent instability. 4, 7, 11 Acquired problems and patient variability can cause significant reductions of plasma PS levels measured by both assays. 4, 11 These factors can reduce the plasma PS levels, but it is unclear if they actually increase the clinical phenotype probability of thrombus formation.
Duebgen et al 7 state their case for the use of PS activity assay first, before measuring free PS antigen. 7 They found that the activity was usually lower than the free PS antigen in known cases of genetic mutation. 7 For most clinical coagulation evaluations, the main goal is to test for function (activity) and, if decreased, to confirm by antigenic assay to determine the type of deficiency (quantitative or qualitative). 2 PS may be an exception because the PS activity assay is influenced by more factors than free PS antigen, including less stable reagents, assay inconsistencies, and unknown patient variables. 2, 4, 11 In our studies, we have found that a high number of falsely low PS activity results are reported if the PS activity is used as the first assay. 11 Of 4 US Food and Drug Administration-approved PS activity assays, the percentage of falsely low PS activity values in healthy people ranged from 10% to 20%. 11 The results were sporadic and unpredictable and were normal if repeated on a new sample. In our laboratory and other special coagulation laboratories in the United States, the initial PS analysis is free PS antigen assay (a surrogate marker of PS activity). 4, 12 When the free PS antigen is less than the reference range, the PS activity assay is performed to confirm the deficiency. 4, 12 This algorithm of PS analysis will eliminate most misdiagnoses of PS deficiency in healthy people because falsely low PS activity values will be avoided. 4, 12 In addition, this algorithm results in significant cost savings by using less "reflex" and repeat testing. 4 A minor disadvantage of free PS antigen might be the rare type II defect not being detected; however, Duebgen et al 7 were able to identify the known PS mutations with the free PS antigen. 4, 7, 12 The type of mutation in PS makes it more difficult to identify a correct diagnosis based on the laboratory assay. Based on the data reported by Duebgen et al, 7 it is unclear about making a diagnosis using the laboratory phenotype as the major evidence to determine a lifelong deficiency. Can we rely on laboratory phenotype testing for the trueness of the PS deficiency? I do not believe so. The laboratory diagnosis of PS deficiency as familial PS deficiency remains difficult to determine. In the study by Duebgen et al, 7 many of the laboratory deficiencies of PS did not have an associated PS gene mutation. We cannot conclude that these low laboratory values are true PS deficiencies, but we also cannot say that they are not. PS is probably the most difficult to assay to perform in coagulation studies. Laboratory phenotype determination is difficult owing to wide variations from preanalytic variables, assay method issues, and unstable reagents in conjunction with acquired abnormalities and patient variability. At this point, the laboratory cannot truly determine PS genotype with absolute certainty.
Obtaining accurate genotype results is difficult with plasma-based PS activity and free PS antigen assays because the assays are prone to many variables from the patient to preanalytic variables to assay reagents. To better correlate the clinical phenotype with the PS genotype, we must circumvent the cause of these major variables by not using plasma-based assays. The most direct way to determine a true PS genetic deficiency is by genetic methods. However, direct genetic analysis is not a realistic method in today's clinical laboratory. Probably, we will have to go to genetics as soon as possible to confirm that the clinical phenotype that may or may not be manifested by the laboratory result is actually caused by a genetic defect.
Can we call a clinical phenotype (thrombosis) as being due to PS genetic deficiency if only the laboratory values are decreased? Must we confirm a genetic defect? These are the main questions addressed Duebgen et al. 7 It seems that it is not correct to assume that moderately decreased levels are a true PS genetic deficiency. We are not even sure that these low PS levels contributed to the cause of the thrombosis. Based on the study by Duebgen et al, 7 it seems that a lower cutoff for the PS reference interval should be considered. Using 3 SD from the average would eliminate a majority of the assumed PS deficiencies that are confined to a genetic mutation. These data and data from the mutation data bank for PS deficiencies should be compared with plasma PS levels to determine if moderately low levels of PS are associated with no mutations. Intermediate between genetics and expression of disease lies the laboratory testing aspect, which is where the problem of true identification of a defect occurs. We are still without true guidance on the use of plasma PS activity and free PS antigen levels in the diagnosis of PS deficiency. This article raises more questions for clinical laboratories but certainly is an insightful investigation into the genetics and measurement arenas. The article tells us that we need to be looking at the diagnostic criteria for PS deficiency from a new perspective. 
